Endobronchial CarcinoidNCT06757920
"Bronchoscopic Argon Plasma Coagulation for Managing Endobronchial Carcinoid Lesions
A study testing bronchoscopic argon plasma coagulation in people with Endobronchial Carcinoid, run by Alexandria University at 1 site in Egypt.
Trial summary
A small tube will go through the respiratory tract and a non contact cauterization will be done to the inside tumor Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Endobronchial Carcinoid
- What is being tested?
- bronchoscopic argon plasma coagulation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2025to 20 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1 - Cooperative patient with written informed consent. 2- Patients diagnosed with endobronchial carcinoid. 3- Patients fit for fiberoptic bronchoscopy. 4- Patients unwilling or unfit for surgery.
Who cannot join
- 1 -Poor karnofsky score. 2- Patients unwilling or unfit for bronchoscopy. 3- Extraluminal lesion. 4- Patients with pacemaker. 5- Forced expiratory volume 1 is less than one litre.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Use of Bronchoscopic Argon Plasma Coagulation in Endobronchial Carcinoid
A small tube will go through the respiratory tract and a non contact cauterization will be done to the inside tumor
Read the detailed description
fiberoptic bronchoscopy will go through the tracheobronchial tree and after localization of the tumor, argon plasma coagulation by initiation non contact electrocautery will be done to the tumor
- Conditions
- Endobronchial Carcinoid
- Being tested
- bronchoscopic argon plasma coagulation
- Keywords
- Argon Plasma Coagulation, fiberoptic bronchoscopy, endobronchial carcinoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bronchoscopic argon plasma coagulationProcedure or surgery
Argon Plasma Cogulation for Debulking Endobronchial Carcinoid Using Fiberoptic Bronchoscopy
| Study group | Role | What they receive |
|---|---|---|
| fiberoptic bronchoscopy in one group | Active comparator | fiberoptic bronchoscopic argon plasma coagulation for palliation of endobronchial carc inoid Receives: Procedure: bronchoscopic argon plasma coagulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dyspnea Borg Scale
scale from 0 to 4 according to the degree of improvement
Measured: one month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2025
- Study start1 Jan 2025
- Primary completion15 Jul 2025
- Study completion20 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endobronchial CarcinoidStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Argon Plasma Coagulation via non contact probe for debulking and fulgration of the endobronchial carcinoid using fiberoptic bronchoscopy
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Sabry, Alexandria University
- Investigators
- mohamed sabry eltarhony, lecturer, Principal investigator, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06757920
- Sponsor's protocol ID
- FOB - Endobronchial Carcinoid
- Status last verified
- Aug 2025
- First submitted
- 27 Dec 2024
- Last updated
- 28 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: because it is against the rules of the chest department
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Use of Bronchoscopic Argon Plasma Coagulation in Endobronchial Carcinoid
- ClinicalTrials.gov ID
- NCT06757920
- Acronym / sponsor ID
- FOB - Endobronchial Carcinoid
- Conditions
- Endobronchial Carcinoid
- Keywords
- Argon Plasma Coagulation, fiberoptic bronchoscopy, endobronchial carcinoid
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 15 Jul 2025 (actual)
- Study completion
- 20 Aug 2025 (actual)
- First posted
- 3 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A small tube will go through the respiratory tract and a non contact cauterization will be done to the inside tumor
Detailed description
fiberoptic bronchoscopy will go through the tracheobronchial tree and after localization of the tumor, argon plasma coagulation by initiation non contact electrocautery will be done to the tumor
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Argon Plasma Coagulation via non contact probe for debulking and fulgration of the endobronchial carcinoid using fiberoptic bronchoscopy
| Arm | Type | Receives |
|---|---|---|
| fiberoptic bronchoscopy in one group | Active comparator | Procedure: bronchoscopic argon plasma coagulationfiberoptic bronchoscopic argon plasma coagulation for palliation of endobronchial carc inoid |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 1 - Cooperative patient with written informed consent. 2- Patients diagnosed with endobronchial carcinoid. 3- Patients fit for fiberoptic bronchoscopy. 4- Patients unwilling or unfit for surgery.
Key exclusion criteria (1 listed)
- 1 -Poor karnofsky score. 2- Patients unwilling or unfit for bronchoscopy. 3- Extraluminal lesion. 4- Patients with pacemaker. 5- Forced expiratory volume 1 is less than one litre.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bronchoscopic argon plasma coagulationArgon Plasma Cogulation for Debulking Endobronchial Carcinoid Using Fiberoptic Bronchoscopy | Procedure or surgery | fiberoptic bronchoscopy in one group |
Primary outcome
Dyspnea Borg Scale
Time frame: one month
scale from 0 to 4 according to the degree of improvement
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2025.
- Successful treatment of endobronchial carcinoid using argon plasma coagulationLink provided by the sponsor.
- Individual participant dataSharing planned: No. because it is against the rules of the chest department
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
mohamed sabry eltarhony, lecturer principal investigator
Alexandria University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing bronchoscopic argon plasma coagulation in people with Endobronchial Carcinoid, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dyspnea Borg Scale (time frame: one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2025.